EGFR L858R and T790M coexistence before first line therapy in pulmonary adenocarcinoma - case report

被引：0

作者：

Sousa, V. ^{[1
]}

Alarcao, A. ^{[1
]}

Ladeirinha, A. F. ^{[1
]}

Reis Silva, M. ^{[1
]}

Balseiro, S. ^{[1
]}

Ferreira, T. ^{[1
]}

d'Aguiar, M. J. ^{[1
]}

Figueiredo, A. ^{[1
]}

Barata, F. ^{[1
]}

Carvalho, L. ^{[1
]}

机构：

[1] UC, IAP, Fac Med, Coimbra, Portugal

来源：

VIRCHOWS ARCHIV | 2018年 / 473卷

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

E-PS-21-02

引用

页码：S315 / S315

页数：1

共 50 条

[31] Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations
Ma, Weijie
Gong, Jay
Shan, Jidong
Lewis, Debbie
Xiao, Wenwu
Moore, Elizabeth H.
Zhang, Yanhong
Hung, Jamie
Mans, Nicole Z.
Wei, Sixi
Welborn, Jenna
Stollenwerk, Nicholas S.
Lam, Kit S.
Li, Tianhong
JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 7
[32] Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
Foschi, Francesca
Tinivella, Annachiara
Crippa, Valentina
Pinzi, Luca
Mologni, Luca
Passarella, Daniele
Rastelli, Giulio
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) : 239 - 245
[33] Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines
Shao, Hanshuang
Wells, Alan
FRONTIERS IN ONCOLOGY, 2023, 13
[34] Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study
Das, Amrita
Biggs, Mary A.
Hunt, Hannah L.
Mahabadi, Vida
Goncalves, Beatriz G.
Phan, Chau Anh N.
Banerjee, Ipsita A.
MOLECULAR DIVERSITY, 2024,
[35] The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
Liang, Hengrui
Pan, Zhenkui
Wang, Wei
Guo, Chengye
Chen, Difei
Zhang, Jianrong
Zhang, Yiyin
Tang, Shiyan
He, Jianxing
Liang, Wenhua
JOURNAL OF THORACIC DISEASE, 2018, 10 (04) : 2311 - +
[36] De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
Fujiwara, Takumi
Kobayashi, Tetsu
Yasuma, Taro
D'Alessandro-Gabazza, Corina N.
Toda, Masaaki
Fujimoto, Hajime
Fujiwara, Kentaro
Takeshita, Atsuro
Nishihama, Kota
Okano, Tomohito
D'Alessandro, Valeria Fridman
Takei, Yoshiyuki
Hataji, Osamu
Gabazza, Esteban C.
CANCERS, 2020, 12 (10) : 1 - 13
[37] Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics
Ansari, Iqrar Ahmad
Debnath, Bimal
Kar, Saikat
Patel, Harun M.
Debnath, Sudhan
Zaki, Magdi E. A.
Pal, Pinaki
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (05): : 2464 - 2481
[38] Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
Sun, Peiyuan
Qu, Yana
Wang, Yuna
Wang, Jing
Wang, Xuanjun
Sheng, Jun
JOURNAL OF CANCER, 2021, 12 (13): : 3900 - 3908
[39] A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures
Das, Agneesh Pratim
Nandekar, Prajwal
Mathur, Puniti
Agarwal, Subhash M.
PROTEIN SCIENCE, 2023, 32 (09)
[40] Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
Wu, Hong
Wang, Aoli
Zhang, Wei
Wang, Beilei
Chen, Cheng
Wang, Wenchao
Hu, Chen
Ye, Zi
Zhao, Zheng
Wang, Li
Li, Xixiang
Yu, Kailin
Liu, Juan
Wu, Jiaxin
Yan, Xiao-E
Zhao, Peng
Wang, Jinhua
Wang, Chu
Weisberg, Ellen L.
Gray, Nathanael S.
Yun, Cai-Hong
Liu, Jing
Chen, Liang
Liu, Qingsong
ONCOTARGET, 2015, 6 (31) : 31313 - 31322

← 1 2 3 4 5 →